VRTX Vertex Pharmaceuticals Incorporated

176.14
+2.55  (+1%)
Previous Close 173.59
Open 174.36
Price To Book 8.93
Market Cap 45,274,222,930
Shares 257,035,443
Volume 762,591
Short Ratio
Av. Daily Volume 1,080,474
Stock charts supplied by TradingView

NewsSee all news

  1. Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Carmen Bozic, M.D., has been appointed as the company's Executive Vice President, Global Medicines Development and Medical Affairs. Dr. Bozic will

  2. Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics

    -Partnership will leverage Ribometrix's discovery platform for up to three therapeutic programs- -Ribometrix to receive $20 million in upfront payment and Vertex equity investment; potential for additional milestones

  3. Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)

    Eligible patients in Scotland will immediately have access to ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today

  4. Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.m. ET. The audio portion of

  5. Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes

    -Semma's unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes patients- -Semma to be acquired

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 positive data released November 27, 2018. 14% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min)
Label expanded to now include all patients over 6 years old - June 21, 2019.
Tezacaftor / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
Phase 2 data released July 18, 2017. ppFEV1 of 12.0 percentage points.
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Approved December 29, 2014.
KALYDECO
Cystic fibrosis (CF) ages 6 and older who have the R117H mutation
Phase 2 primary endpoint met - January 25, 2017.
VX-150
Osteoarthritis
CRL issued February 5, 2016.
KALYDECO (ivacaftor)
Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.
Approved July 2, 2015.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation
Approved March 17, 2015.
KALYDECO (ivacaftor)
Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations
NDA filing due 1Q 2018.
ORKAMBI
Two Copies of the F508del Mutation - children ages 2 to 5
Phase 3 data released October 25, 2017 - primary endpoint not met.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation
Phase 3 trial terminated August 2016
VX-661
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function
Approved September 28, 2016.
ORKAMBI
Cystic fibrosis (CF) ages 6-11 who have F508del mutation
Phase 2 data released July 18, 2017. ppFEV1 of 9.7 percentage points.
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2 data released December 18, 2018. Primary endpoint met.
VX-150
Neuropathic pain
Phase 3 positive data released November 27, 2018. 10% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic Fibrosis Who Have Two Copies of the F508del Mutation
PDUFA date under priority review March 19, 2020.
VX-445 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one copy of the F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 1/2 trial first patient enrolled - noted February 25, 2019.
CTX001
Sickle cell disease
Phase 1/2 initial data due late-2019.
CTX001
Beta-thalassemia
FDA Approval announced August 7, 2018.
Ivacaftor
Cystic fibrosis (CF) ages 2 to 5.
Approval announced August 15, 2018.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 1-2.
FDA Approval announced April 30, 2019.
Ivacaftor
Cystic Fibrosis (6-12 mths)
sNDA filing due late 2018.
Tezacaftor and ivacaftor
Cystic Fibrosis (Age 6-11)
Phase 2 monotherapy trial initiated 2Q 2019.
VX-561
Cystic fibrosis who have a gating mutation
Phase 2 combo trial initiated May 2019.
VX-561 and VX-121
Cystic Fibrosis
Phase 2 trial planned.
VX-814
alpha-1 antitrypsin (AAT) deficiency

Latest News

  1. Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Carmen Bozic, M.D., has been appointed as the company's Executive Vice President, Global Medicines Development and Medical Affairs. Dr. Bozic will

  2. Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics

    -Partnership will leverage Ribometrix's discovery platform for up to three therapeutic programs- -Ribometrix to receive $20 million in upfront payment and Vertex equity investment; potential for additional milestones

  3. Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)

    Eligible patients in Scotland will immediately have access to ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today

  4. Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.m. ET. The audio portion of

  5. Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes

    -Semma's unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes patients- -Semma to be acquired